Analyst Price Targets — TGTX
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| August 4, 2026 10:50 am | Emily Bodnar | H.C. Wainwright | $78.00 | $46.17 | StreetInsider | TG Therapeutics (TGTX) PT Raised to $78 at H.C. Wainwright |
| June 22, 2026 7:56 pm | — | Jefferies | $83.00 | $54.40 | TheFly | TG Therapeutics price target raised to $83 from $57 at Jefferies |
| May 6, 2026 3:54 pm | — | H.C. Wainwright | $70.00 | $39.75 | TheFly | TG Therapeutics price target raised to $70 from $60 at H.C. Wainwright |
| January 15, 2026 12:51 am | — | Goldman Sachs | $39.00 | $29.54 | TheFly | TG Therapeutics price target raised to $39 from $37 at Goldman Sachs |
| October 6, 2025 10:11 am | Emily Bodnar | H.C. Wainwright | $60.00 | $36.71 | TheFly | TG Therapeutics assumed with a Buy at H.C. Wainwright |
| November 5, 2024 11:41 am | Edward White | H.C. Wainwright | $27.50 | $12.93 | StreetInsider | TG Therapeutics (TGTX) PT Raised to $55 at H.C. Wainwright |
| August 6, 2024 6:02 pm | Corinne Jenkins | Goldman Sachs | $20.00 | $20.58 | TheFly | TG Therapeutics price target raised to $20 from $18 at Goldman Sachs |
| May 3, 2024 6:46 am | Edward White | H.C. Wainwright | $24.50 | $8.21 | StreetInsider | TG Therapeutics (TGTX) PT Raised to $49 at H.C. Wainwright |
| February 7, 2023 7:34 am | — | Cantor Fitzgerald | $24.00 | $18.48 | Benzinga | Cantor Fitzgerald Maintains Overweight on TG Therapeutics, Raises Price Target to $24 |
| December 30, 2022 9:21 am | — | Evercore ISI | $16.00 | $11.83 | Benzinga | Evercore ISI Group Maintains Outperform on TG Therapeutics, Raises Price Target to $16 |
Latest News for TGTX
NEW YORK, Sept. 03, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced that Michael S.
TG Therapeutics (TGTX) reported earnings 30 days ago. What's next for the stock?
TG Therapeutics, Inc.'s Q4 2026/H1 2027 will be rich in catalysts. From the presentation of preliminary Phase 1 azer-cel data in progressive MS in the second half of 2026 to topline Phase 3 data for Briumvi SC by year-end 2026/early 2027. TG Therapeutics raised its Briumvi U.S. net product revenue from $885-$900 million to $890-$905 million.
Deutsche Bank AG purchased a new stake in TG Therapeutics, Inc. (NASDAQ: TGTX) in the undefined quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 235,481 shares of the biopharmaceutical company's stock, valued at approximately $12,937,000. Deutsche Bank AG owned 0.15%
Shares of TG Therapeutics rose this week after buyout rumors surfaced. TG is a prime takeover target, fueled by Briumvi's growth and recent subcutaneous formulation de-risking. I see a potential acquisition premium of at least 45-50%, valuing TGTX at $73-76 per share, with strong standalone prospects regardless of M&A outcomes.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for TGTX.
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.